Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]
News [3579]
Articles [92]
Editorials [5]
Conferences [157]
elearning [19]
Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019
Novel therapies in the treatment of bladder cancer
Dr Petros Grivas and Dr Andrea Necchi
Novel therapies in the treatment of bladder cancer ( Dr Petros Grivas and Dr Andrea Necchi )
3 Jun 2019
Clinical and translational results from the NEOSTAR study: Treating early-stage...
Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston...
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2019
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as...
Dr Edward B. Garon - UCLA, Los Angeles, USA
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal...
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona...
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )
1 Jun 2019
Comment: Reasonable to conclude that pembrolizumab is non-inferior to...
Dr Richard Schilsky and Dr Josep Tabernero
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )
1 Jun 2019
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or...
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona...
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )
1 Jun 2019
Comment: The success of immunotherapy means we have to change our mindset as we...
Dr David Graham and Dr Edward B. Garon
Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )
1 Jun 2019
Pembrolizumab is safe and effective and substantially increases overall...
Dr Edward B. Garon - UCLA, Los Angeles, USA
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019
Ovarian cancer: Current treatments and latest advances
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Ovarian cancer: Current treatments and latest advances ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 May 2019
Latest in ovarian cancer treatment
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Latest in ovarian cancer treatment ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 May 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation